# 90-Day Enterprise Atlas Pilot

## Proposed Engagement
- Status: protected-pilot
- Duration: 90 days
- Recommended commercial model: Recommended protected-pilot range: $400k-$1.25M; $1.25M-$2M+ for multi-site, sandbox-planning, or buyer-specific protected diligence scope
- Target buyer: Health systems, payers, governments, and enterprise operators preparing controlled deployment
- Request route: /pilot?offer=clinical-operations-automation-blueprint

## Objective
Design the tenant, governance, interoperability, audit, runtime safety, and value model required for a controlled enterprise deployment.

## Deliverables
- Enterprise Atlas operating model
- Tenant, role, and reviewer design
- Connector and conformance implementation plan
- Runtime safety and durable audit decision register
- Enterprise license and phased deployment proposal

## Included Product Proof
- [Atlas Interoperability Readiness Demo](/demos/atlas-interoperability-readiness): Demonstrate standards-aware synthetic conformance evidence with exact live-use blockers retained.
- [AgentOS Governance Evaluation Demo](/demos/agentos-governance-evaluation): Demonstrate how a synthetic enterprise workflow packet becomes a governed multi-agent plan and Atlas Trust Card.
- [CarePath Access Operations Demo](/demos/carepath-access-operations): Demonstrate how a fragmented high-risk follow-up queue becomes a reviewable operational routing packet.

## Decision Metrics
- Identity and access decisions approved
- Connector scope and conformance plan approved
- Runtime safety and audit owners assigned
- Annual license decision supported by measured value

## Buyer Inputs
- Executive steering sponsor
- Security, privacy, compliance, and legal participation
- Workflow and integration owners
- Approved baseline and value methodology

## Governance Gates
- BAA and data-boundary decisions defined before live data
- Tenant identity and roles approved
- Durable audit and incident response approved
- Human-review procedures approved

## Production Exclusions
- No live clinical execution until every required control is approved
- No unsupported clinical or reimbursement claims
- No connector activation without partner acceptance
- No autonomous diagnosis or treatment

## Product Boundary
SCRIMED demos and pilot programs are governed synthetic evaluations for enterprise buyers. They do not ingest live PHI, diagnose, treat, submit payer transactions, contact patients, mutate production records, or autonomously execute clinical care.

This non-binding proposal is a starting point for enterprise scoping. Final scope, pricing, security requirements, legal terms, success criteria, and production permissions require written buyer and SCRIMED approval.